You are here
IMV Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference
HALIFAX, Nova Scotia, July 25, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq:IMV) (TSX:IMV), a clinical stage immuno-oncology corporation, today announced that IMV Chief Executive Officer Frederic Ors will present a corporate update at the Canaccord Genuity 38th Annual Growth Conference, which takes place August 8-9, 2018, in Boston, MA.
IMV’s presentation details include:
- Date: Wednesday, August 8, 2018
- Time: 10:30 – 10:55 a.m. ET
- Location: Melbourne Room at the Intercontinental Hotel, Boston, MA
There will be a live webcast of IMV’s presentation accessible at http://wsw.com/webcast/canaccord30/imv/. The webcast will be archived for 90 days following the live presentation. A copy of the presentation will be available on the Events & Presentations page of IMV’s website: www.imv-inc.com.
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
Contacts for IMV:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com